SGLT-2 Inhibitors in Heart Failure: Putting the Evidence Into Practice
Following the release at ESC 2021 of updated guidelines for the diagnosis and treatment of acute and chronic heart failure, Prof Andrew Coats (Monash University, Australia and University of Warwick, UK) and Prof Giuseppe Rosano (St George's, University of London, UK) discuss the implications for treatment strategies.
This three-part series provides comprehensive update on some of the most important developments in HFrEF management including addressing key considerations of where SGLT-2 inhibitors fit into the new guidelines for HFrEF, when and how to initiate SGLT-2 inhibitors, and making evidence-based choices in the selection of SGLT-2 inhibitor.
Learning Objectives
- Recall the latest recommendations and levels of evidence supporting the use of SGLT-2 inhibitors in heart failure (HF)
- Consider the impact of delaying the adoption of all guideline-directed foundational therapies in existing HF
- Make an evidence-based choice when selecting an SGLT-2 inhibitor in HF
Target Audience
- Heart failure specialists
- Cardiologists
- Referring physicians
- Allied health professionals
More from this programme
Part 1
Where Do SGLT-2 Inhibitors Fit Into the New Guidelines for HFrEF?
Part 2
When and How to Initiate SGLT-2 Inhibitors in HFrEF
Part 3
Choosing an SGLT-2 Inhibitor – Making an Evidence-based Choice
Faculty Biographies
Andrew JS Coats
Professor of Cardiology and Scientific Director
Professor Andrew Coats was born in Melbourne, Australia. He studied at St Catherine’s College, Oxford, where he earned a B.A. in Physiological Sciences with First-Class Honours, and then completed his medical degree (M.B. B.Chir.) at Clare College, Cambridge. He later obtained higher doctorates (D.M. and D.Sc.) in recognition of his substantial contributions to cardiovascular medicine, and he also completed an MBA at the London Business School. Professor Coats serves as Editor-in-Chief of the Cardiac Failure Review journal.
Career Overview
Andrew Coats is an internationally renowned academic cardiologist, inventor, and university leader with a career spanning more than three decades. He is currently the Scientific Director and CEO of the Heart Research Institute in Sydney, Australia. He also serves as Dean of the Royal Australasian College of Physicians, Affiliate Professor at Deakin University, and Emeritus Professor of Medicine at Monash University.
…
Giuseppe Rosano
Consultant Cardiologist and Professor of Cardiology (Hon)
Giuseppe Rosano was born and raised in Vibo Valentia, Italy, where he developed an early interest in medicine and cardiovascular science. While detailed information about his family and early childhood is not widely published, his Italian background and international academic career reflect strong cultural roots combined with global engagement in cardiovascular medicine.
Academic History
Professor Rosano obtained his Medical Degree in Medicine and Surgery with full honours from La Sapienza University of Rome in 1988. He subsequently completed his specialisation in Cardiology in 1992. Following his clinical training, he pursued advanced academic and research qualifications in the United Kingdom, earning both an MSc and a PhD in Medical Sciences from Imperial College London. His postgraduate research focused on cardiovascular physiology and pharmacology, forming the foundation of his future work in heart failure and cardiac metabolism.